A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19
Dave Singh, Maxim Bogus, Valentyn Moskalenko, Robert Lord, Edmund J. Moran, Glenn Crater, David L. Bourdet, Nathan D. Pfeifer, Jacky Woo, Elad Kaufman, David A. Lombardi, Emily Weng, Tuan S. Nguyen, Ashley Woodcock, Brett Haumann, Rajeev Saggar
Abstract
<b>The inhaled lung-selective pan-JAK inhibitor nezulcitinib appears generally well tolerated in hospitalised patients with severe #COVID-19, with trends for improved oxygenation and clinical status, shortened hospitalisation, and fewer deaths <i>versus</i> placebo</b>https://bit.ly/35Xs1Rf
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Placebo2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Internal medicineLungVirologyPathologyInfectious disease (medical specialty)OutbreakDiseaseAlternative medicineCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchInflammasome and immune disorders